Business
INTERIM RESULTS
NIOX Group PLC reported unaudited interim results for the six months ended 30 June 2025, featuring a 20% increase in revenue to £25.2 million. Clinical revenue grew by 8% to £20.0 million, while research revenue surged by 108% to £5.2 million. Adjusted EBITDA increased by 30% to £9.2 million, resulting in an adjusted EBITDA margin of 36.5%. Adjusted basic earnings per share rose by 31% to 2.26p. Cash generated from operations amounted to £7.0 million. The company's cash balance stood at £11.8 million as of 30 June 2025, and increased to £13.2 million by 31 August 2025, despite paying a £5.0 million dividend in June 2025. Disclaimer*
About this update from Niox Group Plc
[{"type":"text","content":"\n\nNIOX GROUP PLC\n \n(\"NIOX\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\nINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2025\n \nOxford, UK - 30 September 2025: NIOX Group plc (AIM: NIOX), a company engaged in the design, development, and commercialisation of medical devices for the diagnosis, monitoring and management of asthma and COPD, today announces its unaudited interim results for the six months ended 30 June 2025 (\"H1 2025\").\n \nFinancial highlights\n· Revenue growth of 20% (21% on a constant currency basis) to £25.2 million (H1 2024: £21.0 million).\n· Clinical1 revenue growth of 8% (9% on a constant currency basis) to £20.0 million (H1 2024: £18.5 million).\n· Research2 revenue up 108% (108% on a constant currency basis) to £5.2 million (H1 2024: £2.5 million), driven by unforecasted increases in clinical trial activity using FeNO testing for asthma and COPD.\n· Adjusted EBITDA3 of £9.2 million up 30% (H1 2024: £7.1 million), reflecting strong operational leverage driven by higher sales and a broadly flat cost base.\n· Adjusted EBITDA margin 36.5% (H1 2024: 33.8%).\n· Adjusted basic earnings per share of 2.26p up 31% (H1 2024: 1.73p).\n· Cash generated from operations of £7.0 million (H1 2024: £6.0 million).\n· Strong balance sheet with cash of £11.8 million as of 30 June 2025 (30 June 2024: £21.5 million, before £21.0 million returned by way of tender offer, 31 December 2024: £10.9 million), notwithstanding the payment of a £5.0 million dividend in June 2025. Cash at 31 August 2025: £13.2 million.\n \nFinancial progress\n\n\n\n\n \n\n\nH1 2025\n \n£m\n\n\nH1 2024\n \n£m\n\n\n\n\nRevenue\n\n\n25.2\n\n\n21.0\n\n\n\n\nGross margin\n\n\n70%\n\n\n72%\n\n\n\n\nTotal expenditure4\n\n\n(8.5)\n\n\n(8.1)\n\n\n\n\nAdjusted EBITDA3\n\n\n9.2\n\n\n7.1\n\n\n\n\nAdjusted EBITDA margin\n\n\n36.5%\n\n\n33.8%\n\n\n\n\nOperating profit\n\n\n5.8\n\n\n4.2\n\n\n\n\nProfit before tax\n\n\n5.9\n\n\n4.4\n\n\n\n\nProfit for the financial period\n\n\n5.9\n\n\n4.4\n\n\n\n\nCash at period end\n\n\n11.8\n\n\n21.5\n\n\n\n\n1 Clinical revenue represents sales to physicians and hospitals for use in clinical practice.\n2 Res...